Drug
Icatibant clinical trials
Also written Firazyr and HOE-140.
- studies test it
- 24
- open now
- 0
- in phase 3
- 10
- first study started
- 2004
How studies write it
Studies that test it under each name
Brand
Studies by the year they started
24 studies that test it; most in 2009 (4)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 4 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 7
- Phase 3
- 10
- Phase 4
- 4
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 13
Shire (8) · Vanderbilt University Medical Center (5) · Vanderbilt University (2) · University of Edinburgh (2) · QuantumLeap Healthcare Collaborative (1) · Nang Kuang Pharmaceutical Co., Ltd. (1) · GCS Ramsay Santé pour l'Enseignement et la Recherche (1) · Sebastian Videla (1)
Often tested with
Tested in the same studies.
Sacubitril valsartan sodium hydrate (2) · Sacubitril valsartan (2) · Remdesivir (1) · Imatinib (1) · Dexamethasone (1) · Cenicriviroc (1) · Apremilast (1) · Dornase alfa (1)
Studies
Open first, then newest update. How each study uses icatibant is read from its arms, and is right about nine times in ten.
Testing it · 24
- Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 ReceptorActive, not recruitingPhase 3Vanderbilt University Medical CenterNCT05834777Written as Icatibant
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2CompletedPhase 4Vanderbilt University Medical CenterNCT04113109Written as Icatibant
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsActive, not recruitingPhase 2QuantumLeap Healthcare CollaborativeNCT04488081Written as Icatibant
- A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced AngioedemaCompletedPhase 4Nang Kuang Pharmaceutical Co., Ltd.NCT07290855Written as Icatibant Injection (Icanticure®)
- Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).CompletedPhase 2GCS Ramsay Santé pour l'Enseignement et la RechercheNCT05010876Written as Icatibant Injection
- Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) InfectionCompletedPhase 2Sebastian VidelaNCT04978051Written as Firazyr
- A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary AngioedemaCompletedPhase 3TakedaNCT04654351Written as TAK-667
- EASSI - Evaluation of the Safety of Self-Administration With IcatibantCompletedPhase 3ShireNCT00997204Written as Icatibant
- A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)CompletedPhase 3ShireNCT00912093Written as Icatibant
- Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary AngioedemaCompletedPhase 3ShireNCT00097695Written as Icatibant
- Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)CompletedPhase 3ShireNCT00500656Written as Icatibant
- Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced AngioedemaCompletedPhase 3ShireNCT01919801Written as Icatibant
- A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary AngioedemaCompletedPhase 3ShireNCT01386658Written as icatibant
- A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese ParticipantsCompletedPhase 3ShireNCT03888755Written as Icatibant
- Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese VolunteersCompletedPhase 1ShireNCT02045264Written as Icatibant (30 mg)
- Mitochondria and Chronic Kidney DiseaseCompletedPhase 2Vanderbilt University Medical CenterNCT03177798Written as Icatibant
- Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2WithdrawnPhase 2Vanderbilt University Medical CenterNCT03005184Written as Icatibant
- Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated AngioedemaTerminatedPhase 4Vanderbilt University Medical CenterNCT01574248Written as icatibant
- Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAECompletedPhase 4Massachusetts General HospitalNCT01457430Written as Icatibant
- Bradykinin Receptor Blocker in ACE Inhibitor-associated AngioedemaTerminatedPhase 1Vanderbilt UniversityNCT00517582Written as HOE-140
See all 24 studies that test icatibant →
As the comparator · 1 — what is tested is compared with icatibant
Codes
What other systems call icatibant · ClinicalTrials.gg INT003531
- MeSH (NLM) C065679icatibantConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 7PG89G35Q7ICATIBANTConfirmed FDA, NLM, Wikidata
- RxNorm 1148138Confirmed FDA, Wikidata
- Wikidata Q902379icatibantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C98883IcatibantOne source FDA
- DrugBank DB06196One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C065679 | icatibant | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 7PG89G35Q7 | ICATIBANT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1148138 | — | Confirmed FDA, Wikidata |
| Wikidata | Q902379 | icatibant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C98883 | Icatibant | One source FDA |
| DrugBank | DB06196 | — | One source Wikidata |
Also registered as icatibant acetate (UNII 325O8467XK · RxNorm 1294605).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.